F+FreeMedSite USMLELearn with clinical reasoning
SEPARATE VIVA EXTENSION

Dilated cardiomyopathy from anthracycline exposure

Follow-up oral questions and concise, clinically defensible model answers. Your MCQ remains open in its original tab.

← Return to original MCQ
EXAMINER FOLLOW-UP 1

Which protective agent can reduce some anthracycline cardiotoxicity risks?

Dexrazoxane in selected clinical settings.

EXAMINER FOLLOW-UP 2

Which echo measure is routinely followed?

Left ventricular ejection fraction, with global longitudinal strain in appropriate surveillance.

EXAMINER FOLLOW-UP 3

What is the broad mechanistic target implicated?

Topoisomerase IIβ in cardiomyocytes.